Kite Pharma (KITE)

[beambe]

NEW YORK (TheStreet) -- Kite Pharma (KITE_) continued to surge Tuesday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.

Kite treated patients with its an anti-CD19 chimeric antigen receptor (CAR) T cell therapy called KTE-C19. Eight of 13 patients with Advanced B cell malignancies showed complete remissions, while four showed partial remissions. The total result was a 92% objective response rate.

Furthermore, four of seven patients with chemotherapy-refractory diffuse large B-cell Lymphoma showed complete remissions. Three of these cases are ongoing, while one is ongoing after 22 months.








http://www.thestreet.com/story/12857173/1/why-kite-pharma-kite-stock-continues-to-surge-today.html?puc=CNBC&cm_ven=CNBC